Parsons Capital Management Inc. RI Sells 11,650 Shares of Sanofi (NASDAQ:SNY)

Parsons Capital Management Inc. RI decreased its holdings in Sanofi (NASDAQ:SNY) by 45.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,065 shares of the company’s stock after selling 11,650 shares during the period. Parsons Capital Management Inc. RI’s holdings in Sanofi were worth $684,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in SNY. Rise Advisors LLC boosted its holdings in shares of Sanofi by 98.4% in the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after purchasing an additional 251 shares during the period. Salem Investment Counselors Inc. bought a new stake in Sanofi during the 4th quarter valued at $27,000. Venturi Wealth Management LLC lifted its holdings in shares of Sanofi by 163.5% in the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after buying an additional 332 shares during the period. Frazier Financial Advisors LLC bought a new position in shares of Sanofi during the 4th quarter worth $28,000. Finally, Register Financial Advisors LLC purchased a new position in shares of Sanofi during the first quarter valued at $29,000. 10.04% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. TheStreet downgraded Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Finally, Morgan Stanley began coverage on Sanofi in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price objective for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $55.00.

Sanofi Stock Performance

Sanofi stock traded down $0.23 during trading hours on Friday, hitting $49.13. 4,148,180 shares of the stock traded hands, compared to its average volume of 2,214,580. Sanofi has a 1 year low of $42.63 and a 1 year high of $56.26. The stock has a market capitalization of $124.28 billion, a price-to-earnings ratio of 24.69, a P/E/G ratio of 1.48 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. The firm’s 50 day moving average price is $47.71 and its 200-day moving average price is $48.32.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). The business had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a net margin of 10.52% and a return on equity of 19.69%. As a group, equities analysts expect that Sanofi will post 4.09 EPS for the current fiscal year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be paid a dividend of $1.478 per share. This is a boost from Sanofi’s previous annual dividend of $1.38. The ex-dividend date is Thursday, May 9th. This represents a dividend yield of 2.98%. Sanofi’s dividend payout ratio (DPR) is presently 69.35%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.